Sign in
Not yet recruitingPhase 2

AK139 for Chronic Rhinosinusitis With Nasal Polyps

Tests AK139 injections against placebo in adults with chronic rhinosinusitis with nasal polyps.

Key facts

Who runs it
Akeso
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps
Status
Not yet recruiting
Phase
Phase 2
People taking part
75 people, planned
Started
10 Aug 2026
Expected to end
31 Jul 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • AK139
  • Placebo
Record updated
10 August 2026

Who can take part

The trial is looking for adults with long-term sinus inflammation and nasal polyps (growths) in both sides of the nose. Participants also use a steroid nose spray (mometasone furoate) during the trial.

Age
18 to 75 years
Sex
All sexes
Disease stage
Nasal polyps in both sides of the nose. Nasal Polyp Score (NPS) of 5 or more, with at least 2 on each side. Ongoing blocked nose, with a Nasal Congestion Score (NCS) of 2 or 3.
Earlier treatment
Must have had steroid tablets or injections (systemic corticosteroids), or be unable to take them, and/or had nasal polyp surgery before. Must have used a steroid nose spray for at least 4 weeks before screening. Cannot have had certain biologic drugs within 10 weeks or 5 half-lives (whichever is longer), or AK139 before.
Main reasons for not taking part
  • Sinus or nose surgery within 6 months before screening
  • Asthma with FEV1 (a lung test) of 50% or less of the expected value
  • Chronic hepatitis B, hepatitis C, HIV or syphilis; active tuberculosis or autoimmune disease
  • Systemic steroids within 4 weeks (short or medium acting) or 6 weeks (long acting) before screening
  • Earlier anti-IL-4Rα antibody treatment that did not work well enough
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • Male or female participants aged 18 to 75 years (inclusive) at the time of signing the informed consent form (ICF)
  • Bilateral CRSwNP with prior treatment with systemic corticosteroids (SCS), contraindications to or intolerance of SCS, and/or prior nasal polyp surgery
  • Nasal Polyp Score (NPS) ≥5, with a minimum score of 2 in each nasal cavity, at screening and baseline
  • Ongoing nasal congestion/obstruction, with a Nasal Congestion Score (NCS) of 2 or 3 at screening and baseline
  • Use of intranasal corticosteroids for at least 4 weeks prior to screening

Who cannot take part

  • History of sinonasal surgery (including nasal polypectomy) within 6 months prior to screening, or prior nasal surgery resulting in structural changes that preclude adequate assessment of Nasal Polyp Score (NPS)
  • Acute sinusitis, nasal infection, or upper respiratory tract infection within 2 weeks prior to screening or during the screening period
  • Treatment with anti-IL-4Rα monoclonal antibodies, anti-thymic stromal lymphopoietin (TSLP) monoclonal antibodies, anti-immunoglobulin E (IgE) monoclonal antibodies, or other biologic agents within 10 weeks or 5 half-lives (whichever is longer) before randomization, or prior treatment with AK139
  • Treatment with short- or intermediate-acting systemic corticosteroids within 4 weeks prior to screening, or long-acting systemic corticosteroids within 6 weeks prior to screening
  • Prior treatment with anti-IL-4Rα monoclonal antibodies with inadequate clinical response
  • Presence of any of the following conditions:; Antrochoanal polyp; Persistent rhinitis medicamentosa; Allergic fungal rhinosinusitis with symptoms and/or CT findings
  • Nasal malignant or benign tumors
  • Known eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, cystic fibrosis, primary ciliary dyskinesia, or other systemic diseases associated with nasal polyposis
  • Parasitic infection, active tuberculosis, recurrent or chronic infectious diseases, or autoimmune diseases
  • Chronic infection with hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), or syphilis
  • Severe nasal septal deviation causing obstruction of at least one nostril
  • Participants with asthma and FEV1 ≤50% of the predicted value at screening or baseline

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Chronic rhinosinusitis with nasal polyps

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AK139 injection compared with placebo in participants with chronic rhinosinusitis with nasal polyps (CRSwNP) receiving background treatment with mometasone furoate nasal spray (MFNS).

The 3 groups in the trial

  • AK139 regimen 1Treatment being tested

    AK139 regimen 1 will be administered by subcutaneous injection

    Treatment: AK139

  • AK139 regime 2Treatment being tested

    AK139 regime 2 will be administered by subcutaneous injection.

    Treatment: AK139

  • PlaceboPlacebo, for comparison

    Placebo will be administered by subcutaneous injection.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps
Plain-language title
AK139 for Chronic Rhinosinusitis With Nasal PolypsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07755371, who can take part
Record updated
10 August 2026